Alfred Danielian, MD, FACC- Incoming Governor of Nevada speaks out on behalf of AED’s

ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

Please join us for the ACC Rockies Chapter Meeting from September 8-9, 2023 at the Hyatt Centric in Park City, Utah. For more information and to register, please visit: https://web.cvent.com/event/314c67f2-d26f-4ad9-bfd7-8011b1bd9dcb/summary

RSS Latest in Cardiology from ACC.org

  • Colorectal Cancer and HPV Pose Increased CV Risk
    People diagnosed with colorectal cancer are significantly more likely to die of cardiovascular causes than the general population, especially in the first two years after their cancer diagnosis and in people younger than 50 years...
  • ACCEL Lite: The Evolving Therapeutic Landscape in Obesity and the Effect on CV Outcomes
    In this interview, Drs. Richard Chazal and Mikhail Kosiborod explore the rapidly evolving therapeutic landscape of obesity, with a particular focus on the cardiovascular benefits of emerging treatments.
  • ACC.25 Science Explores Plant-Based Diets and Mortality, Sex Differences in CV Health, New Wearables Metric, and More
    Studies being presented at ACC.25 later this week in Chicago, IL, will explore the association between plant-based diets and mortality in patients with cardiometabolic diseases, sex differences in cardiovascular health status and long-term outcomes, a new wearables metric related to cardiovascular disease and much more.
  • Explore NCDR Research at ACC.25
    Several abstracts using data from the NCDR suite of registries will be featured at ACC.25, taking place March 29-31 in Chicago, IL. Explore how investigators leverage NCDR data to test their hypotheses on patient risk factors and outcomes, procedure and treatment trends, diversity, health equity and inclusion, guideline adherence, device, facility and provider characteristics, and […]
  • Withdrawing GDMT in Patients With HF and Improved LVEF Increases Mortality/Morbidity
    In patients with heart failure and improved ejection fraction (HFimpEF), withdrawing vs. continuing guideline-directed medical therapy (GDMT) with renin-angiotensin inhibitors (RASi)/angiotensin receptor–neprilysin inhibitors (ARNi) and mineralocorticoid receptor antagonists (MRA), but not beta-blockers (BB), is significantly associated with worse survival and morbidity at one year...